Vtesse Pharma

About Vtesse Pharma

Vtesse Pharma operated as a specialized biopharmaceutical entity, focusing its resources on the development of treatments for rare and underserved diseases, with a primary concentration on Niemann-Pick Type C1 (NPC) disease and other lysosomal storage disorders. The company was founded in January 2015 by Ben Machielse, who also served as its President and CEO. Vtesse emerged as the first spin-off from Cydan Development, an orphan-drug accelerator, and launched with significant backing from investors including New Enterprise Associates, Pfizer Venture Investments, and Lundbeckfond Ventures.

The company's core business revolved around advancing its lead drug candidate, VTS-270, through the clinical trial pipeline. This product is a specific formulation of (2-hydroxypropyl)-beta-cyclodextrin administered via intrathecal infusion. It was developed to address the neurological manifestations of NPC, a fatal genetic disorder that causes excessive lipid accumulation in the brain and other organs. Vtesse's strategy involved a close collaboration with the National Institutes of Health (NIH), which transferred its Investigational New Drug Application for the compound to Vtesse, allowing the company to proceed with a pivotal Phase 2b/3 clinical trial. The business model was contingent on achieving regulatory approval for VTS-270 and subsequently commercializing it for the small global patient population, which numbers around 3,000 cases. The drug received Breakthrough Therapy Designation from the U.S. FDA and Promising Innovative Medicine (PIM) status in the UK, highlighting its potential.

In a significant milestone, just over two years after its inception, Vtesse Pharma was acquired by Sucampo Pharmaceuticals in April 2017. The transaction was valued at an upfront consideration of $200 million, composed of cash and Sucampo stock, with additional potential royalties contingent on future sales. This acquisition provided Sucampo with Vtesse's promising rare disease pipeline, particularly the late-stage asset VTS-270. The entire Vtesse team was expected to join Sucampo to ensure the continuity of the VTS-270 program. Subsequently, in February 2018, Sucampo Pharmaceuticals, including the assets acquired from Vtesse, was itself acquired by Mallinckrodt plc for approximately $1.2 billion, further integrating the VTS-270 program into a larger pharmaceutical organization.